Search

Your search keyword '"Raudrant D"' showing total 44 results
Start Over Author "Raudrant D" Publisher elsevier bv
44 results on '"Raudrant D"'

1. Impact of preoperative brachytherapy followed by radical hysterectomy in stage IB2 (FIGO 2018) cervical cancer: An analysis of SENTICOL I-II trials

Author

Kissel, M., primary, Balaya, V., additional, Guani, B., additional, Magaud, L., additional, Mathevet, P., additional, Lécuru, F., additional, Uzan, C., additional, Morice, P., additional, Stoeckle, E., additional, Fourchotte, V., additional, Querleu, D., additional, Baron, M., additional, Ott, B., additional, Darai, E., additional, Leveque, J., additional, Lanvin, D., additional, Pomel, C., additional, Marret, H., additional, Leblanc, E., additional, Houvenaeghel, G., additional, Rouanet, P., additional, Descamps, P., additional, Mage, G., additional, Graesslin, O., additional, Baldauf, J.J., additional, Classe, J.M., additional, Raudrant, D., additional, Conri, V., additional, Douvier, S., additional, Barranger, E., additional, Leguevaque, P., additional, Fouché, Y., additional, Boulanger, L., additional, Schott, A.M., additional, and Bouttitie, F., additional

Published
2023
Full Text
View/download PDF

2. Sentinel lymph node biopsy and morbidity outcomes in early cervical cancer: Results of a multicentre randomised trial (SENTICOL-2)

Author

Mathevet, Patrice, primary, Lécuru, Fabrice, additional, Uzan, Catherine, additional, Boutitie, Florent, additional, Magaud, Laurent, additional, Guyon, Frederic, additional, Querleu, Denis, additional, Fourchotte, Virginie, additional, Baron, Marc, additional, Bats, Anne-Sophie, additional, Morice, P., additional, Mathevet, P., additional, Stoeckle, E., additional, Querleu, D., additional, Fourchotte, V., additional, Lécuru, F., additional, Bats, A.S., additional, Baron, M., additional, Graesslin, O., additional, Lévèque, J., additional, Ott, B., additional, Daraï, E., additional, Lanvin, D., additional, Pomel, C., additional, Marret, H., additional, Mage, G., additional, Houvenaeghel, G., additional, Baldauf, J.J., additional, Conri, V., additional, Douvier, S., additional, Delpech, Y., additional, Leblanc, E., additional, Fouché, Y., additional, Boulanger, L., additional, Descamps, P., additional, Classe, J.M., additional, Raudrant, D., additional, and Rouanet, P., additional

Published
2021
Full Text
View/download PDF

3. Pigmentation vulvaire étendue

Author

B. Balme, Raudrant D, Sébastien Debarbieux, S. Ronger-Savle, and Laurent Thomas

Subjects
030207 dermatology & venereal diseases, 03 medical and health sciences, medicine.medical_specialty, 0302 clinical medicine, business.industry, 030220 oncology & carcinogenesis, Medicine, Dermatology, business, medicine.disease, Melanosis, Vulvar Diseases
Published
2016

7. Laparoscopic hysterectomy after concurrent radiochemotherapy in locally advanced cervical cancer compared to laparotomy: A multi institutional prospective pilot study of cost, surgical outcome and quality of life

Author

Baffert, S., primary, Alran, S., additional, Fourchotte, V., additional, Traore, M.A., additional, Simondi, C., additional, Mathevet, P., additional, Loustalot, C., additional, Binelli, C., additional, Jaffre, I., additional, Barranger, E., additional, Dupre, P.F., additional, Ferron, G., additional, Houvenaeghel, G., additional, Leveque, J., additional, Descamps, P., additional, Body, G., additional, Raudrant, D., additional, and Classe, J.M., additional

Published
2016
Full Text
View/download PDF

19. Predictive values of hCG clearance for risk of methotrexate resistance in low-risk gestational trophoblastic neoplasias

Author

You, B., primary, Pollet-Villard, M., additional, Fronton, L., additional, Labrousse, C., additional, Schott, A.-M., additional, Hajri, T., additional, Girard, P., additional, Freyer, G., additional, Tod, M., additional, Tranchand, B., additional, Colomban, O., additional, Ribba, B., additional, Raudrant, D., additional, Massardier, J., additional, Chabaud, S., additional, and Golfier, F., additional

Published
2010
Full Text
View/download PDF

22. Grossesse extra-utérine

Author

Dupuis, O., primary, Clerc, J., additional, Madelenat, P., additional, Golfier, F., additional, and Raudrant, D., additional

Published
2009
Full Text
View/download PDF

30. P2-3 Analyse des facteurs histologiques prédictifs d’une mutation germinale de BRCA1/2 dans le cancer du sein précoce, à partir d’une étude en population

Author

Bonadona, V., primary, Moser, S., additional, Sinilnikova, O.M., additional, Bremond, A., additional, Mathevet, P., additional, Mignotte, H., additional, Martin, A., additional, Bobin, J.Y., additional, Romestaing, P., additional, Raudrant, D., additional, Rudigoz, R.C., additional, Chopin, S., additional, Lenoir, G.M., additional, and Lasset, C., additional

Published
2004
Full Text
View/download PDF

40. Discussion

Author

Thoulon, J.M., primary, Charvet, F., additional, and Raudrant, D., additional

Published
1987
Full Text
View/download PDF

43. Structure and composition of microcalcifications in benign and malignant lesions of the breast: Study by light microscopy, transmission and scanning electron microscopy, microprobe analysis, and X-ray diffraction

Author

Frappart, L., primary, Boudeulle, M., additional, Boumendil, J., additional, Lin, Hu Chi, additional, Martinon, I., additional, Palayer, C., additional, Mallet-Guy, Y., additional, Raudrant, D., additional, Bremond, A., additional, Rochet, Y., additional, and Feroldi, J., additional

Published
1984
Full Text
View/download PDF

44. Immunological tolerance following stem cell transplantation in human fetuses in utero

Author

Daniel Raudrant, Maria Grazia Roncarolo, Jean Louis Touraine, S. Laplace, Touraine, Jl, Raudrant, D, Laplace, S, and Roncarolo, MARIA GRAZIA

Subjects
Transplantation, Fetus, business.industry, medicine.medical_treatment, Hematopoietic Stem Cell Transplantation, Hematopoietic stem cell transplantation, Liver transplantation, Clonal deletion, In utero transplantation, Immune tolerance, Pregnancy, Immunology, Immune Tolerance, Humans, Medicine, Female, Surgery, Stem cell, business
Abstract

FOLLOWING 19 years of experience in postnatal fetal liver transplantation (FLT), we have developed a new therapeutic method, namely the in utero transplantation of stem cells from the human fetal liver. This early transplant takes advantage of the immunological tolerance that exists in young fetal recipients. The six fetuses that we treated were 28, 26, 17, 14, and 12 weeks postfertilization. Three patients had immunodeficiencies, two others had thalassemia major and the last one had Niemann-Pick disease (type A). Donor cells were obtained from 7- to 13-week-old fetuses, with conditions approved by the National Committee for Bioethics. Donors and recipients were not matched. Under ultrasonic visualization, the fetal cells were infused through the umbilical vein of four patients and injected intraperitoneally into the 2 other ones. The first patient, born in 1988, has evidence of engraftment (T lymphocytes of donor origin expressing donor HLA specificities, in the host peripheral blood) and reconstitution of cell-mediated immunity. This child, who had bare lymphocyte syndrome,1 has no clinical manifestation of the disease and lives normally at home. The second child was born in 1989; donor cell engraftment has been proven (distinct HLA phenotype) and the severe immunodeficiency has been corrected to a large degree. One fetus with chronic granulomatous disease developed fatal bradycardia after a second in utero FLT. One fetal patient with thalassemia major had cardiac arrest following the intravenous infusion. The fifth patient, transplanted intraperitoneally at 12 weeks of fetal age, to treat thalassemia major, has evidence of donor cell take (Y chromosome in a female patient) and a partial effect on thalassemia has been obtained (HbA increased up to 30%, 1 year after birth); the proportion of donor versus host cells however tended to decrease over the following years suggesting that, in contrast with immunodeficient patients, thalassemic patients exhibit a selective advantage for the development of host, rather than donor, stem cells. The last patient treated by in utero FLT had Niemann-Pick disease. Engraftment was again obtained (donor HLA phenotype) but due to either the limited number of donor cells or the blood-brain barrier, moderate clinical and metabolic effects were seen, especially in the CNS. In all four patients who were born, no side-effect developed in the mother nor in the fetus. Several advantages appear to be associated with in utero FLT2: increased probability of graft take with development of specific immunological tolerance, ideal isolation of patient (in the uterus), and optimal environment for fetal cell development (in the fetal host). Immunological tolerance, in T cells deriving from donor stem cells, after education within host thymus, was shown to involve clonal deletion for donor antigens (deletion induced by donor dendritic cells and macrophages), and clonal anergy for host antigens (anergy induced by host thymic epithelial cells).3 High IL-10 production persisted for many years and was likely to play a role in the stable chimerism and tolerance maintenance.2

Published
1997

Catalog

Books, media, physical & digital resources
See catalog results